Mercer Global Advisors
CRSP icon

Mercer Global Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Mercer Global Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Buy
15,408
+1,846
+14% +$97.3K ﹤0.01% 1883
2026
Q1 		$645K Sell
13,562
-14,850
-52% -$783K ﹤0.01% 1808
2025
Q4 		$1.49M Buy
28,412
+93
+0.3% +$5.57K ﹤0.01% 1254
2025
Q3 		$1.84M Buy
28,319
+3,437
+14% +$197K ﹤0.01% 1074
2025
Q2 		$1.21M Buy
24,882
+13,512
+119% +$523K ﹤0.01% 1116
2025
Q1 		$387K Buy
11,370
+1,390
+14% +$58.9K ﹤0.01% 1619
2024
Q4 		$393K Sell
9,980
-1,598
-14% -$75.5K ﹤0.01% 1584
2024
Q3 		$528K Buy
11,578
+791
+7% +$40.1K ﹤0.01% 1311
2024
Q2 		$583K Buy
10,787
+447
+4% +$25.9K ﹤0.01% 1223
2024
Q1 		$705K Sell
10,340
-696
-6% -$49.8K ﹤0.01% 1111
2023
Q4 		$691K Buy
11,036
+51
+0.5% +$2.82K ﹤0.01% 1146
2023
Q3 		$499K Buy
10,985
+395
+4% +$20.4K ﹤0.01% 1253
2023
Q2 		$595K Sell
10,590
-2,087
-16% -$118K ﹤0.01% 1153
2023
Q1 		$573K Buy
12,677
+307
+2% +$14.9K ﹤0.01% 1137
2022
Q4 		$503K Buy
12,370
+137
+1% +$7.27K ﹤0.01% 1201
2022
Q3 		$799K Sell
12,233
-920
-7% -$66.7K ﹤0.01% 939
2022
Q2 		$800K Sell
13,153
-235
-2% -$13.8K ﹤0.01% 940
2022
Q1 		$840K Buy
13,388
+8,499
+174% +$534K ﹤0.01% 966
2021
Q4 		$370K Buy
4,889
+714
+17% +$62.4K ﹤0.01% 1359
2021
Q3 		$467K Buy
4,175
+855
+26% +$107K ﹤0.01% 1194
2021
Q2 		$537K Buy
3,320
+372
+13% +$45.2K ﹤0.01% 1110
2021
Q1 		$359K Buy
2,948
+383
+15% +$57.8K ﹤0.01% 1235
2020
Q4 		$393K Buy
+2,565
New +$303K ﹤0.01% 963

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mercer Global Advisors's CRSP Position: Q2 2026 in Review

Mercer Global Advisors increased its CRISPR Therapeutics (CRSP) stake by 14% in Q2 2026, buying an estimated $97.3K and bringing the position to 15,408 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Mercer Global Advisors first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.84M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mercer Global Advisors held 15,408 shares of CRISPR Therapeutics worth $840K as of Q2 2026.
  • Mercer Global Advisors bought 1,846 CRISPR Therapeutics shares in Q2 2026, an estimated $97.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1883 holding.
  • Mercer Global Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Mercer Global Advisors's CRISPR Therapeutics position peaked at $1.84M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.